The Board of Directors of iX Biopharma Ltd. announced that the Board has established a Risk Management Committee (RMC) with effect from 8 November 2017 to assist the Board in the risk governance of the company. The composition of the RMC will be as follows: Ms. Claudia Teo Kwee Yee (Chairman), Non-Executive Independent Director; Mr. Low Weng Keong, Non-Executive Independent Director; and Mr. Albert Ho Shing Tung, Non-Executive Director.